Evaluating Omega-3 Fatty Acids and Low-Dose Aspirin with Dental Cleaning in Smokers Having Stage III Periodontitis

What this Trial Is About

This research aims to evaluate the effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct treatment for smoker patients diagnosed with Stage III periodontitis. The study focuses on comparing clinical periodontal parameters and inflammatory markers like interleukin-1 beta IL-1 in gingival crevicular fluid between test and control groups. It is a randomized, double-blind, placebo-controlled trial designed to assess both clinical and biochemical changes over time. Participants are divided into two groups one receives scaling and root planing SRP followed by daily omega-3 fatty acids EPA 640 mg and DHA 480 mg plus low-dose aspirin 75 mg for 6 months, while the other group receives SRP followed by placebo capsules over the same duration. The treatments are administered orally, and the study monitors periodontal health and inflammatory markers at baseline, 3 months, and 6 months. During the study, participants will undergo assessments of periodontal clinical parameters including plaque index, gingival index, bleeding on probing, probing pocket depth, and clinical attachment level at specified intervals. Gingival crevicular fluid samples will be collected to analyze IL-1 levels or other inflammatory markers. The primary outcomes focus on changes in probing pocket depth and clinical attachment level, while secondary outcomes evaluate changes in inflammatory biomarkers. The total participation duration spans 6 months of treatment and follow-up.

Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis